Pravastatin is useful for prevention of recurrent severe placenta-mediated complications – a pilot study

References

• Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol. 2012;36(1):56–59.
   PubMed Web of Science ®Google Scholar
• ACOG practice bulletin No. 202: gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133(1):e1–e25.
   PubMed Web of Science ®Google Scholar
• Venkatesh KK, Strauss RA, Westreich DJ, et al. Adverse maternal and neonatal outcomes among women with preeclampsia with severe features < 34 weeks gestation with versus without comorbidity. Pregnancy Hypertens. 2020;20:75–82.
   PubMed Web of Science ®Google Scholar
• Colella M, Frérot A, Novais ARB, et al. Neonatal and long-term consequences of fetal growth restriction. Curr Pediatr Rev. 2018;14(4):212–218.
   PubMed Web of Science ®Google Scholar
• Downes KL, Grantz KL, Shenassa ED. Maternal, labor, delivery, and perinatal outcomes associated with placental abruption: a systematic review. Am J Perinatol. 2017;34(10):935–957.
   PubMed Web of Science ®Google Scholar
• Malacova E, Regan A, Nassar N, et al. Risk of stillbirth, preterm delivery, and fetal growth restriction following exposure in a previous birth: systematic review and meta-analysis. BJOG. 2018;125(2):183–192.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Gris JC, de Vries JIP, et al. Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomized controlled trials. Lancet. 2016;388(10060):2629–2641.
   PubMed Web of Science ®Google Scholar
• Gris JC, Chauleur C, Molinari N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomized controlled NOH-PE trial. ThrombHaemost. 2011;106:1053–1061.
   Google Scholar
• Gris JC, Chauleur C, Faillie JL, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. ThrombHaemost. 2010;104:771–779.
   Google Scholar
• Sergio F, Maria Clara D, Gabriella F, et al. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparinplus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy. 2006;25(2):115–27.
   Google Scholar
• Mastrolia SA, Novack L, Thachil J, et al. LMWH in the prevention of preeclampsia and fetal growth restriction in women withoutthrombophilia. A systematic review and meta- analysis. Thromb Haemost. 2016;116(11):868–878.
   PubMedGoogle Scholar
• Llurba E, Bella M, Burgos J, et al. Early prophylactic enoxaparin for the prevention of preeclampsia and intrauterine growth restriction: a randomized trial. Fetal Diagn Ther. 2020;47(11):824–833.
   PubMed Web of Science ®Google Scholar
• Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol. 2009;36(2):279–287.
   PubMed Web of Science ®Google Scholar
• Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80(4):614–620.
   PubMed Web of Science ®Google Scholar
• Haddad B, Winer N, Chitrit Y, Heparin-Preeclampsia (HEPEPE) Trial Investigators, et al. Enoxaparin and aspirin compared with aspirin alone to prevent placenta-mediated pregnancy complications: a randomized controlled trial. Obstet Gynecol. 2016;128(5):1053–1063.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Singh J, Khan Y, et al. A new mouse model to explore therapies for preeclampsia. PLOS One. 2010;5(10):e13663.
   PubMed Web of Science ®Google Scholar
• Costantine MM, Tamayo E, Lu F, et al. Using pravastatin to improve the vascular reactivity in a mouse model of soluble FMS-like tyrosine kinase-1-induced preeclampsia . Obstet Gynecol. 2010;116(1):114–120.
   PubMed Web of Science ®Google Scholar
• Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA. 2011;108(4):1451–1455.
   PubMed Web of Science ®Google Scholar
• Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension. 2011;58(4):716–724.
   PubMed Web of Science ®Google Scholar
• Redecha P, Franzke CW, Ruf W, et al. Neutrophil activation by the tissue factor/FactorVIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipidsyndrome. J Clin Invest. 2008;118:3453–3461.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). J Matern Fetal Neonatal Med. 2016;29(6):855–862.
   PubMed Web of Science ®Google Scholar
• Otten LA, van der Ven K, Kühr M, et al. Pravastatin for prevention of HELLP syndrome: a case report. Medicine. 2017;96(42):e8229.
   PubMed Web of Science ®Google Scholar
• Costantine MM, Cleary K, Hebert MF, Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214(6):720.e1–720.e17.
   PubMed Web of Science ®Google Scholar
• Brownfoot FC, Tong S, Hannan NJ, et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension. 2015;66(3):687–697.
   PubMed Web of Science ®Google Scholar
• Girardi G. Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies. J ReprodImmunol. 2017;124:15–20.
   Google Scholar
• Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, etal. Pravastatin for preventing and treating preeclampsia: a systematic review. Obstet Gynecol Surv. 2018;73(1):40–55.
   PubMed Web of Science ®Google Scholar
• Mendoza M, Ferrer-Oliveras R, Bonacina E, et al. Evaluating the effect of pravastatin in early-onset fetal growth restriction: a nonrandomized and historically controlled pilot study. Am J Perinatol. 2020. DOI:10.1055/s-0040-1713651
   PubMed Web of Science ®Google Scholar
• Lefkou E, Mamopoulos A, Dagklis T, et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016;126(8):2933–2940.
   PubMed Web of Science ®Google Scholar
• Nanovskaya TN, Patrikeeva SL, Paul J, et al. Transplacental transfer and distribution of pravastatin. Am J ObstetGynecol. 2013;209(4):373.e1–5.
   PubMed Web of Science ®Google Scholar
• Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015;350:h1035–1042.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. ObstetGynecol. 2013;122:1122–1131.
   Google Scholar
• Dollberg S, Haklai Z, Mimouni FB, et al. Birth weight standards in the live-born population in Israel. Isr Med Assoc J. 2005;7(5):311–314.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296–1304.
   PubMed Web of Science ®Google Scholar
• Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066–1074.
   PubMed Web of Science ®Google Scholar
• Strauss RS. Adult functional outcome of those born small for gestational age: twenty-six-yearfollow-up of the 1970 British Birth Cohort. JAMA. 2000;283(5):625–632.
   PubMed Web of Science ®Google Scholar
• Gris J-C, Mercier E, Quéré I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103(10):3695–3699.
   PubMed Web of Science ®Google Scholar
• Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J ThrombHaemost. 2009;7(1):58–64.
   PubMed Web of Science ®Google Scholar
• Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018;218(2S):S829–S840.
   PubMed Web of Science ®Google Scholar
• Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622.
   PubMed Web of Science ®Google Scholar
• Costantine MM, Ananth CV. The early developments of preeclampsia drugs. Expert Opin Investig Drugs. 2016;25(8):867–870.
   PubMed Web of Science ®Google Scholar
• Akbar MIA, Yosediputra A, Pratama RE, et al. Pravastatin suppresses inflammatory cytokines and endothelial activation in patients at risk of developing preeclampsia: INOVASIA study. J Matern Fetal Neonatal Med. 2021;31:1–8.
   Google Scholar
• Ahmed A, Williams DJ, Cheed V, StAmP trial Collaborative Group, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG. 2020;127(4):478–488.
   PubMed Web of Science ®Google Scholar